Skip to main content

DirectMeds Acquires Autumn DNA, Expanding into Precision-Based Personalized Wellness

Written by Customer Service on . Posted in Mergers And Acquisitions.

First-of-its-kind integration introduces DNA-based supplement planning to telehealth—positioning DirectMeds as the leader in data-driven, outcome-focused virtual care

SALT LAKE CITY, June 04, 2025 (GLOBE NEWSWIRE) — DirectMeds, a leader in telehealth-driven weight loss treatments, announced the acquisition of Autumn DNA, a personalized supplement company powered by genetic and lifestyle data. The strategic acquisition marks a significant expansion in DirectMeds’ mission to deliver holistic, precision-based wellness solutions to its customer base.

Best known for its affordable, medically supervised GLP-1 programs—including Semaglutide and Tirzepatide—DirectMeds will now offer customers the ability to address nutritional gaps, metabolic function, and long-term health through DNA-informed supplementation. Autumn DNA’s proprietary algorithm analyzes more than 500 health markers to curate billions of possible vitamin combinations, offering highly personalized daily packs that adapt to lifestyle changes.

“Our patients are already transforming their lives through weight loss and other medications,” said Chris Armstrong, CEO of DirectMeds. “With Autumn DNA, we’re giving them the tools to go even deeper—supporting energy, mood, metabolism, and longevity. This isn’t just about prescriptions; it’s about empowering people to feel better from the inside out.”

The new offering provides an end-to-end experience: users receive a home DNA testing kit or upload existing results, complete a lifestyle assessment, and receive customized vitamin packs shipped monthly—which will be integrated within DirectMeds’ existing telehealth and patient portal systems.

“This is a natural evolution for both companies,” said Gianni Lotfi, CEO and Co-founder of Autumn DNA. “We’ve always believed in using cutting-edge science and technology to improve people’s health journeys. With DirectMeds’ provider network and medical infrastructure, we’re expanding the reach of that vision—making personalized wellness more accessible, secure, and seamless than ever.”

Key Features of the Integration Include:

  • Billions of possible supplement combinations based on genetic and lifestyle factors
  • Tailored support packs to address medication-related nutrient depletion
  • HIPAA-compliant data handling and secure at-home DNA testing
  • Streamlined virtual consults and transparent pricing models

This acquisition responds to rising demand among health-conscious consumers seeking individualized care. Many GLP-1 users experience fatigue, nutrient loss, and other side effects that can hinder progress. DirectMeds aims to meet these needs with the same scientific rigor, medical oversight, and ease of access that has powered its growth in the prescription space.

To learn more or access personalized plans, visit: https://directmeds.com/dm-join-autumn/

About DirectMeds

DirectMeds provides telehealth consultations and prescription delivery services focusing on GLP-1-based weight loss and metabolic treatments. With fast turnaround times, personalized care, and transparent pricing, DirectMeds simplifies access to medically guided health solutions.

About Autumn DNA

Autumn DNA delivers personalized nutrition solutions based on an individual’s genetic profile and lifestyle factors. Through advanced algorithmic analysis, Autumn DNA empowers users with precision supplements that adapt over time for long-term health and optimization.

Media Contact:
Chris Armstrong
Chief Executive Officer, DirectMeds
chris@directmeds.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.